Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

Market Cap	34.40B
Revenue (ttm)	511.35M
Net Income (ttm)	-878.57M
Shares Out	459.41M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,721,419
Average Volume	3,692,479
Open	72.60
Previous Close	73.50
Day's Range	72.20 - 75.38
52-Week Range	32.72 - 86.18
Beta	0.27
RSI	45.94
Earnings Date	Aug 29, 2025

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 852
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688192

Financial Performance

In 2024, SHA:688192's revenue was 359.90 million, an increase of 294.24% compared to the previous year's 91.29 million. Losses were -845.96 million, -23.63% less than in 2023.